General

iPSC Line
hPSCreg name	CEBe033-A-12
Cite as: When citing this cell line, please use the hPSCreg name (see Naming Tool ) and the corresponding Research Resource ID (RRID).	CEBe033-A-12
Alternative name(s)	SA001 DP427 KO1
iPSC line type	Human embryonic stem cell (hESC)
Similar iPSC lines	CEBe033-A-13 (SA001 DP427 KO2) CEBe033-A-14 (SA001 DP140 KO1) CEBe033-A-15 (SA001 DP140 KO2) CEBe033-A-16 (SA001 DP140 KO3) CEBe033-A-17 (SA001 DP71 KO1) CEBe033-A-18 (SA001 DP71 KO2) CEBe033-A-19 (SA001 DP71 KO3) CEBe033-A (SA001) WTSIi018-B-28 (DU411) WAe009-A-1C CEBe033-A-8 (SA001_KO_HGPRT_1) CEBe033-A-9 (SA001_KO_HGPRT_2) CEBe033-A-10 (SA001_WT_HGPRT_1) CEBe033-A-11 (SA001_WT_HGPRT_2) CEBe033-A-2 (SA001 Shank3 hetero1) CEBe033-A-3 (SA001 Shank3 Hetero2) CEBe033-A-4 (SA001 Shank3 Hetero3) CEBe033-A-5 (SA001 Shank3 Homo1) CEBe033-A-6 (SA001 Shank3 Homo2) CEBe033-A-7 (SA001 Shank3 Homo3) CEBe033-A-1 (GBA1_hESC_GBA#1-/-_10.18.11) WTSIi018-B-29 (DU414) ITXi006-A-1 (IM-R406W)
Last update	23rd September 2025
User feedback show/hide	Written by on Delete No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	Institut from Stem cell Therapy and Exploration of Monogenic diseases (ISTEM)
External iPSC Databases
BioSamples	SAMEA120250250
General iPSC Information
* Is the cell line readily obtainable for third parties?	Yes Research use: allowed Clinical use: not allowed Commercial use: not allowed
Subclone of	CEBe033-A

iPSC Genetic Modification

Disease/phenotype related modifications

Duchenne muscular dystrophy Synonyms DMD Severe dystrophinopathy, Duchenne type Genetic modifications DMD (target) Type of iPSC Modification Gene knock-out Chromosome location Xp21.2-p21.1 Free text target deletion into exon 3 Delivery method CRISPR-associated (CRISPR/Cas) System

Donor Information

General Donor Information
Sex	male
Phenotype and Disease related information (Donor)
Diseases	No disease was diagnosed.
Other Genotyping (Donor)
Is there genome-wide genotyping or functional data available?	No
External Databases (Donor)
BioSamples	SAMEA104132810

Ethics

Also have a look at the ethics information for the parental line CEBe033-A .

Is there an MTA available for the cell line?	Yes
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above?	Yes
Constraints for use or distribution	Work with human embryonic stem cells requires prior approval by local ethics committees.

hESC Derivation

The source cell information can be found in the parental cell line CEBe033-A.

iPSC Culture Conditions

Surface coating	Vitronectin
Feeder cells	No
Passage method	Mechanically
CO2 Concentration	5 %
Medium	Other medium: Base medium: StemMacs IPS-Brew XF Main protein source: Serum concentration: % Supplements Supplement Amount Unit StemMacs IPS-Brew XF Supplement 10 ml
Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line?	No
Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line?	No
Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line?	Yes

iPSC Characterisation

Analysis of undifferentiated iPSCs

Marker Expression

Marker	Expressed	Immunostaining	RT-PCR	Flow Cytometry	Enzymatic Assay	Expression Profiles
NANOG	Yes
SSEA-4	Yes

Differentiation Potency

Endoderm

Endoderm
Ont Id: UBERON_0000925

In vitro spontaneous differentiation

Marker	Expressed
SOX17	Yes
FOXA2	Yes

Mesoderm

Mesoderm
Ont Id: UBERON_0000926

In vitro spontaneous differentiation

Marker	Expressed
ACTA2	Yes
Brachyury	Yes

Ectoderm

Ectoderm
Ont Id: UBERON_0000924

In vitro spontaneous differentiation

Marker	Expressed
TUBB3	Yes
PAX6	Yes

Genotyping

Karyotyping (iPSC Line)
Has the iPSC line karyotype been analysed?	Yes 46,XY DMD_Karyo.png Passage number: 88 Karyotyping method: Spectral karyotyping
Other Genotyping (iPSC Line)
Is there genome-wide genotyping or functional data available?	Yes SNP typing array No mutations